Navigation Links
Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America

ALEXANDRIA, Va., Sept. 8 /PRNewswire/ -- Oxford Finance Corporation (Oxford), a subsidiary of Sumitomo Corporation, is pleased to announce the addition of Dr. Killu Sanborn to its Business Development group. As director, Business Development, she is responsible for originating loan facilities for life science companies, primarily in western North America.

She has over 20 years of experience as a lender and equity investor, banker, executive and entrepreneur. Her previous positions include managing director at Hercules Technology Growth Capital, senior vice president of Comerica Bank, principal/fund manager at IngleWood Ventures, director of Technology Commercialization at Stratagene and vice president of Business Development at Phenogenex. Over the years, Dr. Sanborn has also advised entrepreneurial boards and management teams on operational, financial and strategic matters.

"Dr. Sanborn is well-known and highly respected in the life science arena," said Christopher A. Herr, managing director for Oxford Finance Corporation. She brings with her a deep understanding of the financing needs of life science companies and will be a great asset to our Business Development team."

About Oxford Finance Corporation

A subsidiary of Sumitomo Corporation, Oxford is a specialty finance firm that provides senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1.5 billion in loans, with lines of credit ranging from $500 thousand to $40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts and North Carolina. For more information visit

SOURCE Oxford Finance Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
2. Oxford BioTherapeutics Appoints Michael Moore as Chairman
3. Oxford Performance Materials Introduces OXPEKK PermettaTM High Performance Polymer Films
4. TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford
5. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
6. Bavarian Nordics Case Against Oxford BioMedica
7. New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses
8. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
9. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
10. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
11. Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):